News
  Date Title View
Dec 8, 2014
BURLINGTON, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it is offering to sell 3,500,000 shares of common stock in an underwritten public offering. Flexion also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock in the p...
Dec 1, 2014
- Company Resumes Recruitment in Pivotal Phase 2b Trial; Initiation of Phase 3 Clinical Trial Planned for Early 2015- Conference Call Scheduled for Tomorrow, December 2, 2014 at 9:00 a.m. ET BURLINGTON, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (F...
Nov 17, 2014
BURLINGTON, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CFO Frederick Driscoll will present at the Stifel Healthcare Conference 2014 on Wednesday, November 19, 2014 at 2:25 p.m. Eastern Time. The conference will take place at the New York Palace Hotel in New York City. To access the liv...
Nov 13, 2014
Recent HighlightsFollowing meeting with U.S. Food & Drug Administration (FDA), announced plans to accelerate initiation of a Phase 3 clinical trial for FX006Bolstered intellectual property (IP) protection for FX006 Achieved progress in addressing questions related to FDA's clinical hold of FX006 BURLINGTON, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE...
Nov 6, 2014
BURLINGTON, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that the company will host a conference call and webcast to report its third-quarter 2014 financial results on Thursday, November 13, 2014, at 4:30 p.m. Eastern Time. The dial-in number for the conference call is toll-free (855) 770-0022...
Sep 17, 2014
- Company to host conference call tomorrow, September 18, 2014 at 9:00 a.m. ET to discuss the clinical hold BURLINGTON, Mass., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the United States Food and Drug Administration (FDA) informed the company yesterday that a clinical hold has been placed o...
Sep 9, 2014
BURLINGTON, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent (No. 8828440), entitled "Corticosteroids for the Treatment of Joint Pain," which provides coverage for FX006, the company's lead clinical product candidate....
Sep 3, 2014
- Company to Host Conference Call Tomorrow, September 4, 2014 at 8:30 a.m. EST, During Which Management Will Discuss Updated Timing and Plans BURLINGTON, Mass., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Based on a recent meeting with the U.S. Food and Drug Administration (FDA) to review the clinical development program for Flexion's lead drug candidat...
Aug 7, 2014
Recent HighlightsAnnounced positive topline results from Phase 2a synovial fluid pharmacokinetic (PK) study of lead clinical candidate FX006Initiated confirmatory Phase 2b clinical trial evaluating FX006 in patients with osteoarthritis (OA) of the kneeAppointed two new Directors to Flexion BoardRecently announced execution of Southwest Research Ins...
Jul 31, 2014
BURLINGTON, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that the company will host a conference call and webcast to report its second quarter 2014 financial results on Thursday, August 7, 2014, at 4:30 p.m. ET. The dial-in number for the conference call is toll-free (855) 770-0022 for domest...
FirstPrevious ...
11
NextLast
= add release to Briefcase